Cencora Inc (COR) Stock Analysis
Verdict: HOLD
Oversold pharmaceutical giant pivoting toward high-margin CAR T distribution while maintaining a low-beta defensive profile.
Investment score: 64/100
Analysis as of
Is Cencora Inc stock worth reviewing? The TradeMates thesis
The model sees an attractive entry point following a 25% drawdown, supported by a significant deal with Kite Pharma and a cheap P/E relative to the broader sector's historical norms.
7-factor investment score
- Valuation: 70/100 (weight 20%)
- Financial Health: 60/100 (weight 15%)
- Technical Momentum: 40/100 (weight 15%)
- Earnings Quality: 65/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 75/100 (weight 15%)
Cencora Inc opportunities and risks
What speaks for COR
- Kite CAR T Distribution Deal
What speaks against COR
- CFO Transition Uncertainty
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| COR | 21.4x | 0.2x | 13.0x | 3.5% | 0.8% | 2.9% |
| MCK | 19.9x | 0.2x | 14.0x | 3.6% | 1.2% | 6.4% |
| CAH | 34.0x | 0.2x | 19.1x | 3.7% | 0.6% | 8.3% |
| HSIC | 23.6x | 0.7x | 12.8x | 29.7% | 3.0% | 4.7% |
| AHCO | n/a | 0.5x | 7.1x | 5.4% | -2.8% | 14.2% |
| ACH | n/a | 0.1x | 6.0x | 41.3% | -39.8% | -83.7% |
| Peer median | 19.9x | 0.2x | 12.8x | 5.4% | 0.6% | 6.4% |
Frequently asked questions about Cencora Inc (COR)
Is COR stock a good investment?
The TradeMates model rates Cencora Inc as HOLD with an investment score of 64/100. The model sees an attractive entry point following a 25% drawdown, supported by a significant deal with Kite Pharma and a cheap P/E relative to the broader sector's historical norms. This is algorithmic model output, not personal investment advice.
Is COR stock a buy?
The TradeMates model verdict for COR is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.